Danaher Corporation (NYSE:DHR) Shares Bought by Atlantic Edge Private Wealth Management LLC

Atlantic Edge Private Wealth Management LLC increased its position in Danaher Corporation (NYSE:DHR - Free Report) by 15.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,884 shares of the conglomerate's stock after buying an additional 1,349 shares during the quarter. Atlantic Edge Private Wealth Management LLC's holdings in Danaher were worth $2,026,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of DHR. Vanguard Group Inc. increased its stake in Danaher by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 59,750,122 shares of the conglomerate's stock worth $13,715,641,000 after purchasing an additional 315,912 shares during the period. Geode Capital Management LLC increased its stake in Danaher by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 13,358,206 shares of the conglomerate's stock worth $3,056,996,000 after purchasing an additional 315,446 shares during the period. Norges Bank purchased a new position in Danaher in the 4th quarter worth approximately $2,130,740,000. Bank of New York Mellon Corp increased its stake in Danaher by 2.3% in the 1st quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock worth $1,800,614,000 after purchasing an additional 194,466 shares during the period. Finally, Northern Trust Corp increased its stake in Danaher by 14.3% in the 4th quarter. Northern Trust Corp now owns 7,934,991 shares of the conglomerate's stock worth $1,821,477,000 after purchasing an additional 992,594 shares during the period. Institutional investors own 79.05% of the company's stock.

Danaher Stock Performance

DHR stock traded down $3.60 during trading on Monday, hitting $199.60. 2,388,352 shares of the company traded hands, compared to its average volume of 3,495,257. The stock's 50-day simple moving average is $195.63 and its 200 day simple moving average is $207.10. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.43 and a quick ratio of 1.05. The company has a market cap of $142.85 billion, a PE ratio of 38.76, a P/E/G ratio of 2.85 and a beta of 0.77. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $281.70.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.26. Danaher had a return on equity of 10.80% and a net margin of 15.81%. The company had revenue of $5.74 billion during the quarter, compared to analysts' expectations of $5.58 billion. On average, equities analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.64%. Danaher's payout ratio is 24.85%.

Insider Activity at Danaher

In related news, EVP Christopher Paul Riley sold 15,805 shares of the business's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the completion of the sale, the executive vice president directly owned 15,179 shares in the company, valued at approximately $3,005,442. The trade was a 51.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Steven M. Rales sold 1,250,000 shares of the business's stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $196.74, for a total value of $245,925,000.00. Following the sale, the chairman owned 3,105,808 shares of the company's stock, valued at $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.20% of the stock is currently owned by insiders.

Analysts Set New Price Targets

DHR has been the topic of a number of analyst reports. Wells Fargo & Company decreased their price target on Danaher from $240.00 to $210.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 23rd. Argus reduced their target price on Danaher from $260.00 to $240.00 in a research note on Wednesday, April 23rd. Wolfe Research reduced their target price on Danaher from $275.00 to $220.00 and set an "outperform" rating on the stock in a research note on Monday, April 7th. Jefferies Financial Group reduced their target price on Danaher from $260.00 to $230.00 and set a "buy" rating on the stock in a research note on Tuesday, April 22nd. Finally, TD Cowen boosted their target price on Danaher from $240.00 to $248.00 and gave the company a "buy" rating in a research note on Wednesday, April 23rd. Four investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Danaher currently has an average rating of "Moderate Buy" and an average target price of $248.61.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.